Nibourel O, Guihard S, Roumier C, Pottier Letter, Terre C, Paquet A beneficial, Peyrouze P, Geffroy S, Quentin S, Alberdi An excellent, Abdelali RB, Renneville An effective, Demay C, Celli-Lebras K, Barbry P, Quesnel B, Castaigne S, Dombret H, Soulier J, Preudhomme C, Cheok MH. Copy-amount data recognized the prognostic ;31(3):555-564.
Mohamed Have always been, Balsat Meters, Koering C, Maucort-Boulch D, Boissel N, Payen-Gay L, Cheok Yards, Mortada H, Auboeuf D, Pinatel C, El-Hamri Meters, Tigaud I, Hayette S, Dumontet C, Cros Age, Flandrin-Gresta P, Nibourel O, Preudhomme C, Thomas X, Nicolini FE, Solly F, Guyotat D, Campos L, Michallet Meters, Ceraulo An excellent, Mortreux F, Wattel Age. Leuk Res. 2017;-28.
Mishima Y, Paiva B, Shi J, Playground J, Manier S, Takagi S, Massoud Yards, Perilla-Glen A good, Aljawai Y, Huynh D, Roccaro Was, Sacco An effective, Capelletti Yards, Detappe Good, Alignani D, Anderson KC, Munshi NC, Do just fine F, Lohr JG, Ha G, Freeman SS, Van Allen EM, Adalsteinsson Va, Michor F, San Miguel JF, Ghobrial I will be. 2017;19(1):218-224.
Minnema MC, Kimby Elizabeth, DSa S, Fornecker LM, Poulain S, Snijders TJ, Kastritis Age, Kremer S, Fitsiori A good, Simon L, Davi F, Lunn M, Castillo JJ, Patterson CJ, Le Garff-Tavernier Yards, Costopoulos M, Leblond V, Kersten MJ, Dimopoulos MA, Treon SP. Guideline toward medical diagnosis, therapy and you will impulse conditions to possess Yahoo-Neel disorder. Haematologica. 2017;102(1):43-51.
Micol JB, Pastore A beneficial, Inoue D, Duployez N, Kim E, Lee South carolina, Durham BH, Chung Yr, Cho H, Zhang XJ, Yoshimi A great, Krivtsov A good, Koche Roentgen, Solary Age, Sinha A beneficial, Preudhomme C, Abdel-Wahab O. ASXL2 is very important getting haematopoiesis and you will acts as an excellent haploinsufficient tumour suppressor within the leukemia. Nat Commun. 2017;8:15429.
Telephone Representative
Meunier Meters, Ancelet S, Lefebvre C, Arnaud J, Garrel C, Pezet Yards, Wang Y, Faure P, Szymanski Grams, Duployez Letter, Preudhomme C, Biard D, Polack B, Cahn JY, Moulis JM, Park S. Activated clean air species membership control NF-kappaB activation from the low serving deferasirox inside erythroid progenitors out of reasonable exposure myelodysplastic syndromes. Oncotarget. 2017;8(62):105510-105524.
Manier S, Salem KZ, Park J, Landau Da, Getz Grams, Ghobrial I will http://datingranking.net/pl/gaydar-recenzja/ be. Genomic difficulty out-of numerous myeloma as well as health-related ramifications. Nat Rev Clin Oncol. 2017;14(2):100-113.
Manier S, Powers JT, Sacco A, Glavey SV, Huynh D, Reagan MR, Salem KZ, Moschetta M, Shi J, Mishima Y, Roche-Lestienne C, Leleu X, Roccaro In the morning, Daley GQ, Ghobrial I’m. This new LIN28B/let-seven axis is a book healing pathway within the several myeloma. Leukemia. 2017;31(4):853-860.
Manier S, Liu CJ, Avet-Loiseau H, Park J, Shi J, Campigotto F, Salem KZ, Huynh D, Glavey SV, Rivotto B, Sacco A, Roccaro Have always been, Bouyssou J, Minvielle S, Moreau P, Facon T, Leleu X, Weller Elizabeth, Trippa L, Ghobrial I am. Prognostic part from circulating exosomal miRNAs from inside the several myeloma. Blood. 2017;129(17):2429-2436.
TET2 exon dos bypassing are an independent beneficial prognostic factor getting cytogenetically regular acute myelogenous leukemia (AML): TET2 exon dos skipping for the AML
Manier S, Huynh D, Shen YJ, Zhou J, Yusufzai T, Salem KZ, Ebright RY, Shi J, Park J, Glavey SV, Devine WG, Liu CJ, Leleu X, Quesnel B, Roche-Lestienne C, Snyder JK, Brown Le, Grey N, Bradner J, Whitesell L, Porco JA, Jr., Ghobrial I am. Suppressing new oncogenic interpretation program is an effectual healing strategy in the several myeloma. Sci Transl Med. 2017;9(389).
Magnez Roentgen, Thiroux B, Taront S, Segaoula Z, Quesnel B, Thuru X. PD-1/PD-L1 binding degree using microscale thermophoresis. Sci Associate. 2017;7(1):17623.
Lacombe F, Campos L, Allou K, Arnoulet C, Delabarthe A beneficial, Dumezy F, Feuillard J, Genevieve F, Guerin E, Kid J, Jouault H, Lepelley P, Maynadie M, Solly F, Ballon OW, Preudhomme C, Baruchel A good, Dombret H, Ifrah N, Bene MC. Prognostic worth of multicenter move cytometry matched up comparison out of restricted residual disease during the serious myeloblastic leukemia. Hematol Oncol. 2017.